BioArctic AB
- Biotech or pharma, therapeutic R&D
BioArctic is a Swedish research-based biopharma company focusing on generating innovative drugs that improve the lives of patients with disorders of the central nervous system. We develop drugs with the potential to revolutionize the treatment of disorders such as Alzheimer’s disease, Parkinson’s disease, and ALS, as well as advanced technology to facilitate the passage of drugs across the blood-brain barrier.
BioArctic’s proprietary technology platform, dedicated personnel and external collaborations have made it possible to develop innovative treatments based on antibodies (immunotherapy) for neurodegenerative disorders, exampled by LEQEMBI (lecanemab), an amyloid beta-directed antibody and the world’s first fully approved disease modifying treatment for Alzheimer’s disease.
The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market and out-licensing potential.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}